ClinicalTrials.gg
Drug

Nevirapine clinical trials

Also written Viramune.

studies test it
98
open now
1
in phase 3
31
first study started
1998

Counted the way a researcher would: Nevirapine with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.

This browser remembers your choice.

How each study uses Nevirapine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Nevirapine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
21 Jun 1996 · VIRAMUNE · NDA 020636 (FDA, Drugs@FDA)
European Union
4 Feb 1998 · Viramune · EMEA/H/C/000183 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Nevirapine
74
NVP
14
Nevirapine (NVP)
4
Nevirapine XR
3

Brand

Viramune
9

Studies by the year they started

74 studies that test it; most in 2006 (10)

Studies that test Nevirapine, by start year
YearStudies
19983
19994
20013
20024
20035
20048
20058
200610
20079
20083
20095
20101
20113
20121
20143
20153
20161

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
22
Phase 2
20
Phase 3
31
Phase 4
22
No phase
7

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 33 · Other 65

National Institute of Allergy and Infectious Diseases (NIAID) (28) · Boehringer Ingelheim (26) · Harvard School of Public Health (HSPH) (2) · Germans Trias i Pujol Hospital (2) · International Maternal Pediatric Adolescent AIDS Clinical Trials Group (2) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (2) · Bamrasnaradura Infectious Diseases Institute (2) · Bristol-Myers Squibb (2)

Often tested with

Tested in the same studies.

Lamivudine (23) · Zidovudine (21) · Lopinavir-ritonavir drug combination (13) · Stavudine (10) · Ritonavir (9) · Efavirenz (9) · Didanosine (7) · Atazanavir (6)

Related medicines

As reviewed, each with the page that says it.

Studies

Open first, then newest update. How each study uses Nevirapine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 98

See all 98 studies that test Nevirapine →

Given beside what is tested · 4 — Nevirapine is usual care or a partner of the new treatment
As the comparator · 5 — what is tested is compared with Nevirapine

Codes

What other systems call Nevirapine · ClinicalTrials.gg INT008731

  • MeSH (NLM) D019829NevirapineConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 99DK7FVK1HNEVIRAPINEConfirmed FDA, NLM, Wikidata
  • RxNorm 53654Confirmed FDA, Wikidata
  • Wikidata Q263713nevirapineConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C29277NevirapineOne source FDA
  • DrugBank DB00238One source Wikidata

Also registered as nevirapine hemihydrate (UNII B7XF2TD73C · RxNorm 2462459).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.